Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center
- 1 January 2007
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (1), 180-182
- https://doi.org/10.1080/10428190601007570
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaLeukemia, 2004
- Transplantation as salvage therapy for high-risk patients with myeloma in relapseBone Marrow Transplantation, 2002
- Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapyBlood, 2002
- Treatment Approaches for Relapsing and Refractory Multiple MyelomaActa Oncologica, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Primary plasma cell leukaemiaBritish Journal of Haematology, 1994
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Plasma cell leukemia: An evaluation of response to therapyAmerican Journal Of Medicine, 1987